Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Egypt / NCT06816641
Recruiting Not applicable

Surgical Evacuation Of Spontaneous Intracerebral Hematoma: Clinical Outcomes and Prognostic Factors

NCT06816641 · tracked via the Priya Life Science Egypt tracker
Sponsor
Sohag University
Phase
Not applicable
Started
2022-01-01
Last updated
2025-02-11

Condition(s) studied

Intracerebral Haemorrhage (ICH)

Investigational drug(s) / intervention(s)

Surgical Evacuation of Intracerebral Hemorrhage

Surgical Evacuation of Intracerebral Hemorrhage: Surgical Evacuation of Intracerebral Hemorrhage

Study summary

The aim of this study is to assess the safety and efficacy of surgical evacuation of spontaneous intracerebral hemorrhage.

Eligibility

Sex
ALL
Min age
20 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria: * • Patients with radiological findings of ICH. * Age group 20-70 years. Exclusion Criteria: * • Traumatic ICH or ruptured aneurysm or AVM or brain tumor. * Postoperative cranial surgery ICH. * Secondary hydrocephalus. * Patients with other comorbidities e.g., Liver cell failure and renal cell failure. * Patients with bleeding disorders. * Patients who are regular on anticoagulant or antiplatelet therapy. * Small sized ICH\< 30 ml. * GCS less than 6 preoperatively.

Primary outcome measure(s)

  • Morbidity after surgical evacuation of Intracerebral hematoma — 1 month
    Complications within first month
  • Mortality after surgical evacuation of Intracerebral hematoma — 1 month
    Death of patient within first month

Trial sites (1)

FacilityCityRegionStatus
Sohag University hospitals Sohag Egypt Recruiting

More Sohag University trials in Egypt

Colitis Patterns in Patients With Lower GI Symptoms Starting soon
Zadek Osteotomy for Treatment of Haglund's Syndrome Recruiting
Effects of Dexmedetomidine Combined With Lidocaine Topical Administration on Cough Reflex During Extubation in Thyroidectomy Patient. Active, not recruiting
Toxoplasma Gondii Seroprevalence Among Children With Some Neuropsychiatric Disorders Starting soon
Accuracy of Transabdominal Ultrasound in Predicting Intraperitoneal Adhesions Prior to Laparoscopy Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06816641 on ClinicalTrials.gov ↗ ← All trials in Egypt